Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study

被引：0

作者：

Mauro, Michael ^{[1
]}

Hochhaus, Andreas ^{[2
]}

Hughes, Timothy ^{[3
,4
]}

Rea, Delphine ^{[5
]}

Boquimpani, Carla ^{[6
]}

Minami, Yosuke ^{[7
]}

Apperley, Jane ^{[8
]}

Garcia-Gutierrez, Valentin ^{[9
]}

Kapoor, Shruti ^{[10
]}

Espurz, Noemi ^{[11
]}

Dhamal, Vishal ^{[12
]}

Cortes, Jorge ^{[13
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Univ Klinikum Jena, Jena, Germany

[3] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia

[4] Univ Adelaide, Adelaide, SA, Australia

[5] Hop St Louis, Paris, France

[6] State Inst Hematol Arthur Siquiera Cavalcanti, HEMORIO, Rio De Janeiro, Brazil

[7] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[8] Ctr Haematol Imperial Coll London, London, England

[9] Hosp Univ Ramon & Cajal IRYCIS, Serv Hematol, Madrid, Spain

[10] Novartis Pharmaceut, E Hanover, NJ USA

[11] Novartis Pharma AG, Basel, Switzerland

[12] Novartis Healthcare Private Ltd, Hyderabad, India

[13] Georgia Canc Ctr, Augusta, GA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

CML; asciminib; TKI; ASCEMBL; phase III;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CML-398

引用

页码：S340 / S340

页数：1

共 50 条

[21] Matching-Adjusted Indirect Comparisons (MAICs) of Asciminib vs Other Tyrosine Kinase Inhibitors (TKIs) in Third- or Later-Line Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Atallah, Ehab
Jadhav, Kejal
Kangappaden, Teresa
Damon, Andrea
Samjoo, Imtiaz
Wei, David
Bhattacharyya, Devarshi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S337 - S337
[22] Prognostic significance of prior best response to imatinib in patients (pts) with chronic myeloid leukemia (CML) in chronic phase (CP)Treated with second generation tyrosine kinase inhibitors (TKIs)
Jabbour, Elias
Kantarjian, Hagop
Shan, Jenny
O'Brien, Susan
Wierda, William
Ravandi, Farhad
Borthakur, Gautant
Komblau, Steven
Walker, Brenda K.
Rios, Mary Beth
Cortes, Jorge
BLOOD, 2007, 110 (11) : 577A - 577A
[23] Outcome after Discontinuation of Second Generation Tyrosine Kinase Inhibitors (TKIs) Used As Frontline Therapy for Patients (pts) with Chronic Phase (CP) Chronic Myeloid Leukemia (CML)
Abdelall, Waleed
Kantarjian, Hagop M.
Devendra, K. C.
Akosile, Mary
Borthakur, Gautam
Verstovsek, Srdan
Daver, Naval
Pemmaraju, Naveen
Naqvi, Kiran
Garcia-Manero, Guillermo
Thompson, Philip A.
Ferrajoli, Alessandra
Ravandi, Farhad
Konopleva, Marina
DiNardo, Courtney D.
Jabbour, Elias J.
Cortes, Jorge E.
BLOOD, 2017, 130
[24] Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study
Atallah, Ehab L.
Visotcky, Alexis
Flynn, Kathryn E.
Zhang, Mei-Jie
Radich, Jerald P.
Yang, Jay
Oehler, Vivian G.
Tantravahi, Srinivas K.
Smith, B. Douglas Douglas
Ibarz, Javier Pinilla
Sweet, Kendra
Mauro, Michael
Druker, Brian J.
Thompson, James E.
Maldonado-Schmidt, Sonia
Baim, Arielle
Schiffer, Charles A.
Kota, Vamsi K.
Cortes, Jorge E.
BLOOD, 2022, 140 : 3885 - 3886
[25] Ponatinib As Frontline Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Jain, Preetesh
Kantarjian, Hagop M.
Jabbour, Elias
Borthakur, Gautam
Pemmaraju, Naveen
Daver, Naval
Gachimova, Evguenia
Ferrajoli, Alessandra
Kornblau, Steven M.
Ravandi, Farhad
O'Brien, Susan
Cortes, Jorge E.
BLOOD, 2014, 124 (21)
[26] Ponatinib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP)
Cortes, Jorge E.
Borthakur, Gautam
Pemmaraju, Naveen
Daver, Naval
Quintas-Cardama, Alfonso
Ravandi, Farhad
Gachimova, Evguenia
Estrov, Zeev
Jabbour, Elias
O'Brien, Susan
Kantarjian, Hagop
BLOOD, 2013, 122 (21)
[27] Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Followup from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population
Mauro, Michael
Minami, Yosuke
Hochhaus, Andreas
Lomaia, Elza
Voloshin, Sergei
Turkina, Anna
Kim, Dong-Wook
Apperley, Jane F.
Cortes, Jorge
Abdo, Andre N. R.
Fogliatto, Laura Maria
Kim, Dennis Dong Hwan
le Coutre, Philipp
Saussele, Susanne
Annunziata, Mario
Hughes, Timothy P.
Chaudhri, Naeem A.
Chee, Lynette C. Y.
Gutierrez, Valentin Garcia
Sasaki, Koji
Freitas, Carla Maria Boquimpani De Moura
Kapoor, Shruti
Espurz, Noemi
Dhamal, Vishal
Rea, Delphine
BLOOD, 2023, 142
[28] Real-World Treatment Patterns Among Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cycling Through Multiple Tyrosine Kinase Inhibitors (TKIs) in the United States (US)
Kota, Vamsi
Maegawa, Rodrigo
Latremouille-Viau, Dominick
Jadhav, Kejal
Rossi, Carmine
Guerin, Annie
Iorga, Serban
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S300 - S301
[29] Outcomes of Chronic Phase Chronic Myeloid Leukemia (CP-CML) after Sequential Treatment with Tyrosine Kinase Inhibitors (TKI)
Kong, Jee Hyun
Winton, Elliott F.
Heffner, Leonard
Gaddh, Manila
Hill, Brittany
Arellano, Martha L.
El-Rassi, Fuad
Kim, Audrey
Kota, Vamsi
BLOOD, 2017, 130
[30] Imatinib dose escalation is effective in patients with chronic myeloid leukemia in chronic phase (CML-CP)
Kantarjian, Hagop M.
Druker, Brian J.
Guilhot, Francois
Cortes, Jorge
O'Brien, Stephen G.
Krahnke, Tillmann
Larson, Richard A.
BLOOD, 2007, 110 (11) : 317A - 317A

← 1 2 3 4 5 →